<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Elevated plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (<z:chebi fb="0" ids="17230">Hcy</z:chebi>) concentrations are associated with increased risk of systemic <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e>, <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Several cross-sectional reports and two prospective clinical studies have recently reported elevated plasma <z:chebi fb="0" ids="17230">Hcy</z:chebi> levels in <z:chebi fb="3" ids="15765">L-dopa</z:chebi>-treated <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) patients and <z:chebi fb="0" ids="17230">Hcy</z:chebi> has been proposed as a possible mediator for the development of long-term <z:chebi fb="3" ids="15765">L-dopa</z:chebi> motor complications (such as wearing off and on-off phenomena, and <z:hpo ids='HP_0100660'>dyskinesias</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the study was to elucidate a possible role of <z:chebi fb="3" ids="15765">L-dopa</z:chebi>-related <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> in the development of <z:hpo ids='HP_0100660'>dyskinesias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: In this cross-sectional study we compared <z:chebi fb="0" ids="17230">Hcy</z:chebi>, B(12) and <z:chebi fb="3" ids="37445">folate</z:chebi> levels in 53 PD patients treated with <z:chebi fb="3" ids="15765">L-dopa</z:chebi> (29 with <z:hpo ids='HP_0100660'>dyskinesias</z:hpo>, 24 without <z:hpo ids='HP_0100660'>dyskinesias</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mean plasma <z:chebi fb="0" ids="17230">Hcy</z:chebi> levels were higher in the group of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> patients with <z:hpo ids='HP_0100660'>dyskinesias</z:hpo> (19 vs. 15.4 micromol/L; T: 2.12; p=0.04) </plain></SENT>
<SENT sid="5" pm="."><plain>After taking into account potential confounding factors, analysis of the data revealed that the occurrence of <z:hpo ids='HP_0100660'>dyskinesias</z:hpo> progressively increased with plasma <z:chebi fb="0" ids="17230">Hcy</z:chebi> levels (relative risk 1.2, 95% CI 1.015-1.4; p=0.03) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Our results raise the possibility that <z:chebi fb="0" ids="17230">Hcy</z:chebi> plays a role in the development of <z:hpo ids='HP_0100660'>dyskinesias</z:hpo>, through its toxic effects on both dopaminergic neurons and non-substantia nigra, non-dopaminergic neurons </plain></SENT>
</text></document>